Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After Taxus Liberté Paclitaxel-Eluting Coronary Stent Placement | Zendy

Kirk N. Garratt | Zendy; W. Douglas Weaver | Zendy; Ronald G. Jenkins | Zendy; Thomas Pow | Zendy; Laura Mauri | Zendy; Dean J. Kereiakes | Zendy; Kenneth J. Winters | Zendy; Thomas Christen | Zendy; Dominic J. Allocco | Zendy; David P. Lee | Zendy

Open Access

Prasugrel Plus Aspirin Beyond 12 Months Is Associated With Improved Outcomes After Taxus Liberté Paclitaxel-Eluting Coronary Stent Placement

Author(s) -

Kirk N. Garratt,

W. Douglas Weaver,

Ronald G. Jenkins,

Thomas Pow,

Laura Mauri,

Dean J. Kereiakes,

Kenneth J. Winters,

Thomas Christen,

Dominic J. Allocco,

David P. Lee

Publication year - 2014

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.114.013570

Subject(s) - prasugrel , medicine , thienopyridine , myocardial infarction , cardiology , aspirin , stent , hazard ratio , clopidogrel , confidence interval

The TAXUS Liberté Post Approval Study (TL-PAS) contributed patients treated with TAXUS Liberté paclitaxel-eluting stent and prasugrel to the Dual Antiplatelet Therapy Study (DAPT) that compared 12 and 30 months thienopyridine plus aspirin therapy after drug-eluting stents.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research